Vericel Corporation announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025.
Total revenue expected to be $276 million with MACI revenue at $239.5 million.
Strong growth in MACI revenue and business highlights in 2025.
Revenue Expectation
Total net revenue expected to be $276 million with MACI net revenue of $239.5 million and Burn Care net revenue of $36.5 million.
Profitability
GAAP Net Income profitability expected for the second consecutive year.
Cash and Investments
Vericel reported having $200 million in cash and investments, with no debt.
MACI Growth
Continued growth in MACI revenue with more than 900 MACI-trained surgeons at year-end 2025.
Future Plans
Progressing towards mid-term financial targets with plans for MACI commercial manufacturing in a new facility in 2026.
- Vericel Corporation demonstrated strong financial performance in 2025 with revenue exceeding expectations and continued growth in MACI revenue.
- The company's profitability and financial position indicate stability and potential for future expansion.
- Business highlights show Vericel's successful execution and growth strategies in the sports medicine and severe burn care markets.
Vericel Corporation's preliminary 2025 financial results reflect a successful year with strong revenue, profitability, and growth in key business segments. The company's focus on innovation and market expansion positions it well for continued success in the future.